Advanced Cell Technology, Inc.
MarketLine (a Datamonitor Company)
12 Aug 2013
Available for Immediate Download
Advanced Cell Technology, Inc. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Advanced Cell Technology, Inc. required for business and competitor intelligence needs - Intelligence on Advanced Cell Technology, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Advanced Cell Technology, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Advanced Cell Technology (ACT) is a biotechnology company that applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies. ACT primarily operates in the US, where it is headquartered in Santa Monica, California and employs around 30 people. The company recorded revenues of $0.5 million in the fiscal year ended December 2011, a decrease of 30.2% compared to 2010. The company's operating loss was $21.1 million in fiscal 2011, as compared to an operating loss of $32.3 million in 2010. Its net loss was $72.8 million in fiscal 2011, as compared to the net loss of $54.4 million in 2010. Reasons to Purchase: - Gain understanding of Advanced Cell Technology, Inc. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Advanced Cell Technology, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Advanced Cell Technology, Inc. your competitors' business structure, strategy and prospects